What is Momenta Pharmaceuticals' stock symbol?
Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."
Where is Momenta Pharmaceuticals' stock going? Where will Momenta Pharmaceuticals' stock price be in 2017?
9 equities research analysts have issued 12-month price objectives for Momenta Pharmaceuticals' stock. Their predictions range from $6.00 to $20.00. On average, they anticipate Momenta Pharmaceuticals' stock price to reach $16.56 in the next year.
When will Momenta Pharmaceuticals announce their earnings?
Momenta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.
What are analysts saying about Momenta Pharmaceuticals stock?
Here are some recent quotes from research analysts about Momenta Pharmaceuticals stock:
- Aegis analysts commented, "Warning letter delivered from FDA to fill/finish manufacturer. On Friday after market close, Momenta announced that Pfizer, Sandoz's contracted manufacturer for Glatopa, had received an FDA warning letter. While the facility is a key portion of Momenta's supply chain for Glatopa 20mg, the warning letter is not expected to restrict production or shipments. Since the Pfizer facility is where the final Glatopa 40 mg product will be manufactured, FDA policy states that compliance observations must be satisfactorily resolved before the ANDA can move forward. We anticipate this will translate into a 6-month delay for Glatopa 40 mg." (2/21/2017)
Maxim Group analysts commented, "The District Court of Delaware ruled to invalidate several of Teva’s (TEVA- $33.43-Hold) patents protecting 40mg (3x weekly) Copaxone; Patents ‘250, ‘413, ‘302, and ‘776. In 2016, the Patent Trial and Appeal Board (PTAB) declared these patents invalid due to obviousness through an inter partes review (IPR) proceeding." (2/1/2017)
According to Zacks Investment Research, "Momenta received a boost with the FDA approval of Glatopa (a generic version of Copaxone; 20 mg). The drug has captured nearly 40% of the once-daily Copaxone (20 mg) market. Momenta’s efforts to develop its biosimilars pipeline are also impressive. The company has a partnership with Mylan for six of the latter’s biosimilar. Moreover, we are encouraged by the company’s collaboration with Sandoz. The company also has an exclusive research collaboration and worldwide license agreement with CSL Limited for M230. Momenta’s share price has outperformed the Zacks classified Biomedical and Genetics industry in the last twelve months. However, the discontinuation of patient enrolment in a phase II study on necuparanib on the recommendation of an independent Data Safety Monitoring Board following the unfavorable outcome of a planned interim futility analysis is disappointing." (1/16/2017)
Who owns Momenta Pharmaceuticals stock?
Momenta Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (15.49%), BlackRock, Inc (11.60%), Discovery Capital Management LLC CT (6.48%), Orbimed Advisors LLC (4.28%), Fiera Capital Corp (2.88%) and State Street Corp (2.72%). Company insiders that own Momenta Pharmaceuticals stock include Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, James M Roach, John E Bishop, Michael Franken and Richard P Shea.
Who sold Momenta Pharmaceuticals stock? Who is selling Momenta Pharmaceuticals stock?
Momenta Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Fiera Capital Corp, Dimensional Fund Advisors LP, Oxford Asset Management, Discovery Capital Management LLC CT, Commerzbank Aktiengesellschaft FI, Numeric Investors LLC, Turner Investments LLC and Envestnet Asset Management Inc.. Company insiders that have sold Momenta Pharmaceuticals stock in the last year include Bruce Leicher, Craig A Wheeler, Ganesh Venkataraman Kaundinya, James M Roach, John E Bishop and Richard P Shea.
Who bought Momenta Pharmaceuticals stock? Who is buying Momenta Pharmaceuticals stock?
Momenta Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Opaleye Management Inc., Arrowstreet Capital Limited Partnership, State Street Corp, Renaissance Technologies LLC, Palo Alto Investors LLC, FMR LLC and Guggenheim Capital LLC.
How do I buy Momenta Pharmaceuticals stock?
Shares of Momenta Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Momenta Pharmaceuticals stock cost?
One share of Momenta Pharmaceuticals stock can currently be purchased for approximately $15.10.